Ready-to-Use Potassium Phosphate Solutions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current potassium phosphate solutions for intravenous administration are often concentrated, requiring dilution and posing risks due to aluminum toxicity, chemical instability, and the need for continuous monitoring, with complex preparation procedures that increase the risk of error and contamination.
Innovation Solution
Development of ready-to-use, sterile potassium phosphate solutions in a flexible polymeric container with a suitable tonicity agent, reduced aluminum content, and a desirable phosphate to potassium ratio, eliminating the need for dilution and providing enhanced storage stability and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of moving object
If concentrated potassium phosphate solutions are used for intravenous administration, then the volume of fluid to be administered is reduced, but the risk of aluminum toxicity and chemical instability increases
Solution Approach 1:
The patent changes the concentration parameter of potassium phosphate solutions from conventional high concentrations (10-30 mmol/100mL) to a specific intermediate concentration range (15-45 mmol/100mL with phosphorus 15-30 mmol/100mL and potassium 20-40 mEq/100mL). This parameter optimization reduces aluminum content to ≤10 mcg/L while maintaining chemical stability and providing ready-to-use formulations without requiring dilution.
2Stability of the object's composition
If concentrated potassium phosphate solutions are used, then storage stability is improved, but the risk of crystallization and precipitation increases
Solution Approach 1:
The patent optimizes the concentration parameters within the range of phosphorus 15-30 mmol/100mL and potassium 20-40 mEq/100mL, which maintains the solution below saturation points that would cause crystallization. This parameter range ensures long-term storage stability without precipitation while providing sufficient phosphorus replacement therapy.
Solution Approach 2:
The patent uses composite buffer systems containing multiple components (phosphate buffers, pH adjusters, and stabilizers) working together to maintain chemical stability. The combination of potassium phosphate with appropriate buffers and chelating agents creates a synergistic formulation that prevents crystallization while maintaining stability during storage and administration.
3Ease of operation
If ready-to-use solutions are developed, then the complexity of preparation procedures is reduced, but the manufacturing and formulation complexity increases
Solution Approach 1:
The patent combines multiple functions into a single ready-to-use formulation: phosphorus replacement, potassium supplementation, pH buffering, and aluminum chelation are all integrated into one solution. This merging eliminates the need for separate compounding steps, dilution procedures, and multiple catheter preparations, simplifying clinical operation while requiring sophisticated formulation development.
Data Source
AI summary
Ready-to-use (RTU) potassium phosphates solutions for phosphorus replacement therapy are presented that include potassium phosphate and sodium chloride at a fixed volume with 1.5 to 15 mmol/100 mL phosphorus, no more than 22 mEq/100 mL potassium and less than 50 mcg/L aluminum.